Enfamil Necrotizing Enterocolitis Lawsuit Set for Trial to Begin This Week

A federal court has rejected a dismissal motion filed by Mead Johnson, the manufacturer of Enfamil infant formula, in an ongoing necrotizing enterocolitis (NEC) lawsuit. The judge found that federal law does not preempt the claims, allowing jury selection to proceed imminently.

Mead Johnson and Abbott Laboratories, makers of Similac, collectively face more than 800 federal lawsuits alleging that their specialized cow's milk-based infant formulas were marketed to hospitals for premature infants without adequate warnings about increased NEC risk. Plaintiffs contend that the manufacturers failed to disclose the dangers of these products to both medical institutions and parents.

Necrotizing enterocolitis is a serious bacterial infection that attacks intestinal walls, causing tissue death. Preterm infants are particularly vulnerable due to underdeveloped gastrointestinal systems. The condition often requires aggressive antibiotic treatment and surgical removal of affected intestinal sections, frequently resulting in severe long-term complications and ongoing medical needs for survivors.

This is a curated brief from the PlaintiffWire news desk. Read the original report at AboutLawsuits.